Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
PRTA 
Prothena Corporation plc (PRTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: PRTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.17% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 837.26M USD | Price to earnings Ratio - | 1Y Target Price 50 |
Price to earnings Ratio - | 1Y Target Price 50 | ||
Volume (30-day avg) 352747 | Beta 0.08 | 52 Weeks Range 11.70 - 31.03 | Updated Date 02/21/2025 |
52 Weeks Range 11.70 - 31.03 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.46 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-02-10 | When After Market | Estimate -1.0411 | Actual -1.08 |
Profitability
Profit Margin -90.5% | Operating Margin (TTM) -3056.85% |
Management Effectiveness
Return on Assets (TTM) -15.54% | Return on Equity (TTM) -23.34% |
Valuation
Trailing PE - | Forward PE 64.1 | Enterprise Value 312815163 | Price to Sales(TTM) 6.19 |
Enterprise Value 312815163 | Price to Sales(TTM) 6.19 | ||
Enterprise Value to Revenue 2.35 | Enterprise Value to EBITDA -3.58 | Shares Outstanding 53808700 | Shares Floating 37711938 |
Shares Outstanding 53808700 | Shares Floating 37711938 | ||
Percent Insiders 16.23 | Percent Institutions 102.05 |
AI Summary
Prothena Corporation plc: A Comprehensive Overview
Company Profile:
History and Background:
Prothena Corporation plc (NASDAQ: PRTA) is a late-stage clinical biotechnology company founded in 2004 and headquartered in Dublin, Ireland. The company focuses on developing and commercializing novel therapeutic proteins for the treatment of severe, life-threatening diseases, with a primary focus on rare and debilitating neurological and inflammatory diseases.
Core Business Areas:
Prothena's core business areas include:
- Neurodegenerative diseases: The company's lead product candidate, PRX004, is in Phase 3 development for the treatment of Alzheimer's disease.
- Inflammatory diseases: Prothena is also developing PRX005 for the treatment of autoimmune diseases such as lupus and myasthenia gravis.
- Hematology: The company has a research program focused on developing therapies for hematologic malignancies.
Leadership and Corporate Structure:
Prothena's leadership team includes:
- Gene Kinney, Ph.D.: Chief Executive Officer and Chairman of the Board
- Sean Bohen, Ph.D.: President and Chief Operating Officer
- David Keiserman, M.D.: Chief Medical Officer
- Jonathan Violin, Ph.D.: Chief Scientific Officer
Prothena has a Board of Directors composed of experienced individuals with expertise in the pharmaceutical and biotechnology industries. The company operates through subsidiaries in the United States, Switzerland, and Ireland.
Top Products and Market Share:
- PRX004: A recombinant human anti-amyloid beta antibody in Phase 3 development for the treatment of Alzheimer's disease. There are currently no approved therapies that specifically target and remove amyloid beta plaques, a hallmark of Alzheimer's disease.
- PRX005: A human monoclonal antibody in Phase 2 development for the treatment of autoimmune diseases such as lupus and myasthenia gravis.
Prothena does not currently have any marketed products, and therefore, no market share data is available.
Total Addressable Market:
The global market for Alzheimer's disease treatments was estimated at $6.4 billion in 2022 and is projected to reach $10.2 billion by 2027. The global market for autoimmune disease treatments was estimated at $147.5 billion in 2022 and is projected to reach $224.5 billion by 2027.
Financial Performance:
Prothena is a clinical-stage company with no marketed products. As a result, the company has yet to generate significant revenue. In 2022, Prothena reported a net loss of $127.3 million, compared to a net loss of $93.5 million in 2021. The company's cash and cash equivalents as of December 31, 2022, were $248.7 million.
Dividends and Shareholder Returns:
Prothena does not currently pay dividends. The company's stock price has been volatile in recent years, reflecting the company's clinical-stage development status.
Growth Trajectory:
Prothena's future growth will be driven by the success of its clinical development programs, particularly for PRX004 and PRX005. The company's recent $225 million financing round in September 2023 provides Prothena with the necessary resources to advance its clinical programs through key milestones.
Market Dynamics:
The market for Alzheimer's disease and autoimmune disease treatments is highly competitive, with several large pharmaceutical companies developing therapies in these areas. However, Prothena's focus on innovative and differentiated therapeutic approaches could give the company a competitive advantage.
Competitors:
- Alzheimer's disease: Biogen (BIIB), Eli Lilly (LLY), Roche (RHHBY)
- Autoimmune diseases: AbbVie (ABBV), Bristol Myers Squibb (BMY), GlaxoSmithKline (GSK)
Potential Challenges and Opportunities:
- Challenges: Clinical development risks, competition, regulatory hurdles, and market access.
- Opportunities: Large and growing addressable markets, potential for significant market share gains, and strategic partnerships.
Recent Acquisitions:
Prothena has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an analysis of various financial and market factors, Prothena Corporation plc receives an AI-based fundamental rating of 7 out of 10. This rating reflects the company's promising clinical development pipeline, strong cash position, and experienced management team. However, the company's lack of marketed products and volatile stock price present some risks for investors.
Sources and Disclaimers:
This overview is based on information from the following sources:
- Prothena Corporation plc website: https://www.prothena.com/
- Prothena Corporation plc SEC filings: https://www.sec.gov/edgar/search/
- Market research reports
This information should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.
Disclaimer:
I am an AI chatbot and cannot provide financial advice.
About Prothena Corporation plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2012-12-21 | President, CEO & Director Dr. Gene G. Kinney Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.prothena.com |
Full time employees - | Website https://www.prothena.com | ||
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.